Tome Biosciences Presented Data on its Programmable Genomic Integration Technologies at ASGCT
May 10, 2024 06:00 ET | Tome Biosciences
Tome presented data updates on its programmable genomic integration technologies at ASGCT.
Tome Biosciences Announces US Patent Issued for Integrase-Mediated Programmable Genomic Integration
April 09, 2024 08:08 ET | Tome Biosciences
Tome granted US patent for programmable genomic integration.
Tome Biosciences Forms Science and Technology Advisory Committee
March 04, 2024 08:00 ET | Tome Biosciences
Tome forms Science and Technology Advisory Committee.
Tome Biosciences Appoints Industry Veteran Daniel Curran, MD, to its Board of Directors
January 30, 2024 08:00 ET | Tome Biosciences
Tome Biosciences appoints Daniel Curran, MD, to its Board of Directors.
Tome Biosciences Acquires Replace Therapeutics
January 02, 2024 09:00 ET | Tome Biosciences
Tome acquires Replace Therapeutics.
Tome Biosciences Launches with Over $200 Million in Funding to Advance Programmable Genomic Integration Platform
December 12, 2023 07:57 ET | Tome Biosciences
Tome Biosciences launches with over $200 million in funding to advance programmable genomic integration (PGI).